This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The
Abstract Introduction Catheter-based radiofrequency (RF) ablation is generally regarded as the standard approach for patients with ventricular tachycardia (VT) refractory to antiarrhythmic drug therapy and may be considered as a first-line approach when there is a preference to avoid these agents.
Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. One clinically nonsignificant PV stenosis occurred in the VHPSD group. Data comparing PFA to VHPSD-PVI is lacking.
The term, VT mapping has been in vogue in clinical electrophysiology for more than half a century, right from Dr.Josephson and Wellens’ days. While , treating VTs with drugs is still a choice, permanent solutions by defining the VT circuit and ablating them, is the new norm. How can we remember this EP lesson easily ?
Method and Results A 54-year-old man with long history of atrial fibrillations developed PVS secondary to multiple radiofrequency ablation procedures. The stenosis was treated with a stent. Balloon angioplasty seems to be the widely preferred treatment of choice. He has since remained asymptomatic over 3 years of follow-up.
Session 104) - What Is Really New in Electrophysiology That Will Change My Practice? The Guidelines Sessions at ACC.24 24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
Results A 27-year-old male with dextrocardia with double outlet right ventricle, subaortic ventricular septal defect, and pulmonary stenosis status-post pulmonary valve replacement complicated by ventricular pacing dependence and subsequent atrial pacing dependence after atriotomy-based atypical flutter ablation developed recurrent mediastinitis and (..)
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:Pulsed field ablation (PFA) is a promising treatment for atrial fibrillation. There were no incidences of adverse event fistula, diaphragmatic paralysis, MI, pericarditis, thromboembolism, PV stenosis, transient ischemic attack, or death.
Research is also underway into algorithms for the diagnosis of Aortic Stenosis and Myocarditis and should be ready for commercialization in the next 18 – 36 months.
ABSTRACT Introduction The safety and efficacy of paroxysmal atrial fibrillation (PAF) ablation with the HELIOSTAR multielectrode radiofrequency (RF) balloon catheter have been demonstrated in European studies; data from elsewhere are lacking. Image is courtesy of Biosense Webster, Inc., part of Johnson & Johnson MedTech.
MANIFEST-17K provides confidence that, unlike conventional thermal ablation, PFA with the pentaspline catheter does not cause the most feared complication of AF ablation—esophageal damage—nor does it cause pulmonary vein stenosis or persistent injury to the diaphragm,” says senior author Vivek Reddy, MD , The Leona M.
Scott Rankin Associations Between Surgical Ablation and Operative Mortality After Mitral Valve Procedures The Annals of Thoracic Surgery June 2018 A. Chris Malaisrie Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting The Journal of Thoracic and Cardiovascular Surgery June 2018 J.
Scott Rankin 1 Associations Between Surgical Ablation and Operative Mortality After Mitral Valve Procedures The Annals of Thoracic Surgery June 2018 A. Chris Malaisrie Burden of preoperative atrial fibrillation in patients undergoing coronary artery bypass grafting The Journal of Thoracic and Cardiovascular Surgery June 2018 J.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content